Monika E Hegi

Monika E Hegi

UNVERIFIED PROFILE

Are you Monika E Hegi?   Register this Author

Register author
Monika E Hegi

Monika E Hegi

Publications by authors named "Monika E Hegi"

Are you Monika E Hegi?   Register this Author

81Publications

3185Reads

5Profile Views

The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.

Drug Resist Updat 2019 03 22;43:29-37. Epub 2019 Apr 22.

Department of Neurosurgery, Brain Tumor Center Amsterdam, Amsterdam University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HZ, Amsterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drup.2019.04.002DOI Listing
March 2019

Improving survival in molecularly selected glioblastoma.

Lancet 2019 02 14;393(10172):615-617. Epub 2019 Feb 14.

Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)33211-2DOI Listing
February 2019

Glioma epigenetics: From subclassification to novel treatment options.

Semin Cancer Biol 2018 08 21;51:50-58. Epub 2017 Nov 21.

Laboratory of Brain Tumor Biology and Genetics, Neuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital, 1066 Epalinges, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2017.11.010DOI Listing
August 2018

In vivo characterization of brain metabolism by H MRS, C MRS and FDG PET reveals significant glucose oxidation of invasively growing glioma cells.

Int J Cancer 2018 07 21;143(1):127-138. Epub 2018 Feb 21.

Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery and Neuroscience Research Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31299DOI Listing
July 2018

Toward methylation-based classification of central nervous system tumors.

Neuro Oncol 2018 04;20(5):579-581

Department of Pathology and Center for Cancer Research, Massachusetts General Hospital, Broad Institute of Harvard and MIT, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892157PMC
April 2018

Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity.

Oncotarget 2017 Dec 30;8(66):110490-110502. Epub 2017 Nov 30.

Department of Clinical Neurosciences, University Hospital Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/22798
Publisher Site
http://dx.doi.org/10.18632/oncotarget.22798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746398PMC
December 2017

Correlation of immune phenotype with IDH mutation in diffuse glioma.

Neuro Oncol 2017 Oct;19(11):1460-1468

Institute of Neurology, Medical University of Vienna, Vienna, Austria; Department of Medicine I, Medical University of Vienna, Vienna, Austria; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Department of Genome Science, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia; Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery & Neuroscience Research Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737620PMC
October 2017

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Neuro Oncol 2017 Aug;19(8):1119-1126

Tel-Aviv Sourasky Medical Center, Tel-Aviv University; European Organization for Research and Treatment of Cancer, Brussels (EORTC); National Institutes of Health (M.R.M.); University of Alabama at Birmingham; Princess Margaret Cancer Centre, University of Toronto; Lausanne University Hospital; NRG Oncology Statistics and Data Management Center; Odette Cancer Centre and Sunnybrook Health Sciences Centre, University of Toronto; Samsung Medical Center, Sungkyunkwan University School of Medicine; Edinburgh Cancer Centre; Mayo Clinic; Robert-Janker Clinic at the University of Bonn Medical Centre, and MAASTRO clinic, GROW School for Oncology, Maastricht University Medical Centre; Miami Cancer Institute; Erasmus University Hospital; Dana-Farber Cancer Institute and Harvard Medical School; University of Zurich.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570239PMC
August 2017

Current management of low-grade gliomas.

Curr Opin Neurol 2016 12;29(6):782-788

aDepartment of Clinical Neurosciences bDepartment of Oncology, Centre Hospitalier Universitaire Vaudois & Lausanne University, Lausanne, Switzerland cDepartment of Radiation-Oncology (MAASTRO), Maastricht University Medical Center (MUMC) and GROW (School for Oncology), Maastricht, Netherlands dDepartment of Radiation-Oncology, MediClin Robert-Janker-Clinic & Clinical Cooperation Unit Neurooncology, University Bonn Medical Centre, Bonn, Germany *Andreas F. Hottinger, Monika E. Hegi and Brigitta G. Baumert contributed equally to the article.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0000000000000390DOI Listing
December 2016

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.

J Mol Diagn 2016 05 27;18(3):350-361. Epub 2016 Feb 27.

Department of Neurosurgery, Lausanne University Hospital, Lausanne, Switzerland; Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2015.11.009DOI Listing
May 2016

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Neuro Oncol 2015 Nov 15;17(11):1425-7. Epub 2015 Sep 15.

Neuroscience Research Center, and Service of Neurosurgery, Lausanne University Hospital, Lausanne (CHUV) (M.E.H); Department of Oncology, University Hospital Zurich, Zurich, Switzerland (R.S).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648310PMC
November 2015

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Neuro Oncol 2015 Aug 29;17(8):1064-75. Epub 2014 Oct 29.

Institute of Neurology, Medical University of Vienna, Vienna, Austria (A.S.B., G.R., A.W., J.A.H.); Department of Medicine I, Medical University of Vienna, Vienna, Austria (A.S.B., O.R., M.F., A.B., C.C.Z., C.M., M.P.); Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (A.S.B., B.K., G.W., O.R., G.R., A.W., K.D., M.F., A.B., C.C.Z., C.M., J.A.H., M.P.); Department of Neurosurgery, Medical University of Vienna, Vienna, Austria (B.K., G.W.); Department of Radiotherapy, Medical University of Vienna, Vienna, Austria (K.D.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery, Department of Clinical Neurosciences, University Hospital Lausanne (CHUV), Lausanne, Switzerland (S.K., M.E.H.); Neurology Clinic and National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany (W.W.); Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany (W.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490866PMC
August 2015

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Neuro Oncol 2015 May 11;17(5):708-17. Epub 2015 Mar 11.

University of Alabama at Birmingham, Birmingham, Alabama (L.B.N.); Baylor University Medical Center, Dallas, Texas (K.L.F.); Henry Ford Hospital, Detroit, Michigan (T.M.); Clinic for Neurosurgery, Clinical Center of Serbia, Medical Faculty University of Belgrade, Belgrade, Serbia (D.G.); Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch, Radiotherapy and Chemotherapy Clinic, Gliwice, Poland (R.T.); Samsung Medical Center, Seoul, South Korea (D.H.N.); Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland (M.M.); St. Luke's Brain Tumor Center, St. Luke's Hospital, Kansas City, Missouri (M.S.); Barrow Neurological Institute, Phoenix, Arizona (L.A.); Medical Oncology Unit 1, IOV, IRCCS, Padova, Italy (V.Z.); Policlinico di Modena, Modena, Italy (R.D.); Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (J.R.P.); Merck KGaA, Darmstadt, Germany (C.H., M.P.); Department of Clinical Neurosciences, University Hospital Lausanne, Lausanne, Switzerland (M.E.H.); Institute of Pathology, University Hospital Lausanne, Lausanne, Switzerland (B.L.); Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou356DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482861PMC
May 2015

Molecular insights into brain tumors: ready for translation into novel treatment strategies?

Authors:
Monika E Hegi

Curr Opin Neurol 2013 Dec;26(6):678-80

Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery, Department of Clinical Neurosciences, University Hospital Lausanne (CHUV), Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0000000000000038DOI Listing
December 2013

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

J Clin Oncol 2013 Nov 7;31(32):4085-91. Epub 2013 Oct 7.

Mark R. Gilbert, Kenneth D. Aldape, Terri S. Armstrong, Jeffrey S. Wefel, Anita Mahajan, and Paul D. Brown, University of Texas MD Anderson Cancer Center; Terri S. Armstrong, University of Texas Health Science Center-School of Nursing, Houston, TX; Meihua Wang and Minhee Won, Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA; Roger Stupp and Monika E. Hegi, Lausanne University Hospitals, Lausanne, Switzerland; Kurt A. Jaeckle, Mayo Clinic Florida, Jacksonville, FL; Deborah T. Blumenthal, Tel Aviv Medical Center, Tel Aviv; Tzahala Tzuk-Shina, Rambam Medical Center, Haifa, Israel; Christopher J. Schultz, Medical College of Wisconsin, Milwaukee, WI; Sara Erridge, University of Edinburgh, Edinburgh, Scotland; Brigitta G. Baumert, Maastricht University Medical Center, Maastricht, the Netherlands; Kristen I. Hopkins, University Hospitals Bristol, Bristol, United Kingdom; Arnab Chakravarti, Arthur G. James Cancer Hospital/Ohio State University Comprehensive Cancer Center, Columbus, OH; Walter J. Curran Jr, Emory University Winship Cancer Center, Atlanta, GA; and Minesh P. Mehta, University of Maryland, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.6968DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816958PMC
November 2013

Neuro-oncology: in search of molecular markers of glioma in elderly patients.

Nat Rev Neurol 2013 Aug 2;9(8):424-5. Epub 2013 Jul 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2013.127DOI Listing
August 2013

Molecular neuro-oncology in clinical practice: a new horizon.

Lancet Oncol 2013 Aug;14(9):e370-9

Department of Neurology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70168-2DOI Listing
August 2013

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.

Neuro Oncol 2013 Mar 20;15(3):269-78. Epub 2012 Dec 20.

Department of Biomedicine, University of Bergen, Jonas Lies vei 91, N-5009, Bergen, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nos301DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578482PMC
March 2013

Brain cancer in 2012: Molecular characterization leads the way.

Nat Rev Clin Oncol 2013 Feb 8;10(2):69-70. Epub 2013 Jan 8.

Division of Neurosurgery, Department of Clinical Neurosciences, University of Lausanne Hospital, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.240DOI Listing
February 2013

Epidermal growth factor receptor: a re-emerging target in glioblastoma.

Curr Opin Neurol 2012 Dec;25(6):774-9

Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery, Department of Clinical Neurosciences, University Hospital Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0b013e328359b0bcDOI Listing
December 2012

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Lancet Oncol 2012 Sep 8;13(9):916-26. Epub 2012 Aug 8.

Division of Cell Biology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Unit of Advanced Palliative Home Care, County Council of Östergötland, Linköping, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(12)70265-6DOI Listing
September 2012

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Neuro Oncol 2012 Sep;14 Suppl 4:iv100-8

Department of Neurology, University Hospital Zurich and Center for Neurosciences, University of Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nos206DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480248PMC
September 2012

DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Neuro Oncol 2012 Jun 8;14(6):701-11. Epub 2012 May 8.

Laboratory of Brain Tumor Biology and Genetics, Department of Clinical Neurosciences, University Center of Legal Medicine, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nos072DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367844PMC
June 2012

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

Clin Cancer Res 2011 Jan 19;17(2):255-66. Epub 2010 Nov 19.

Laboratory of Brain Tumor Biology, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1931DOI Listing
January 2011

Molecular diagnostics of gliomas: the clinical perspective.

Acta Neuropathol 2010 Nov 23;120(5):585-92. Epub 2010 Sep 23.

Department of Neurology, University Hospital Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-010-0750-6DOI Listing
November 2010

MGMT promoter methylation in malignant gliomas.

Target Oncol 2010 Sep 20;5(3):161-5. Epub 2010 Aug 20.

Department of Neuropathology, Heinrich-Heine-University, Moorenstr. 5, 40225 Duesseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-010-0153-6DOI Listing
September 2010

Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?

Future Oncol 2010 Sep;6(9):1407-14

Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.10.113DOI Listing
September 2010

Combining chromosomal arm status and significantly aberrant genomic locations reveals new cancer subtypes.

Cancer Inform 2009 12;7:91-104. Epub 2009 Mar 12.

Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664703PMC
http://dx.doi.org/10.4137/cin.s2144DOI Listing
May 2010

Marker-independent identification of glioma-initiating cells.

Nat Methods 2010 Mar 21;7(3):224-8. Epub 2010 Feb 21.

Division of Neurosurgery, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nmeth.1430DOI Listing
March 2010

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Nat Rev Neurol 2010 Jan 8;6(1):39-51. Epub 2009 Dec 8.

Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrneurol.2009.197
Publisher Site
http://dx.doi.org/10.1038/nrneurol.2009.197DOI Listing
January 2010

Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome.

Int J Cancer 2009 Dec;125(11):2624-30

Department of Neurosurgery, Laboratory of Brain Tumor Biology and Genetics, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.24639DOI Listing
December 2009

Epigenetic deregulation of DNA repair and its potential for therapy.

Clin Cancer Res 2009 Aug 11;15(16):5026-31. Epub 2009 Aug 11.

Laboratory of Brain Tumor Biology and Genetics, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1169DOI Listing
August 2009

Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.

PLoS One 2009 Jun 17;4(6):e5947. Epub 2009 Jun 17.

Laboratory of Brain Tumor Biology and Genetics, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005947PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694268PMC
June 2009

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

Int J Cancer 2008 Sep;123(5):1215-8

Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.23632DOI Listing
September 2008

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

J Clin Oncol 2008 Sep;26(25):4189-99

Laboratory of Tumor Biology and Genetics, Department of Neurosurgery BH-19-110, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH-1011 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/26/25/4189.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2007.11.5964
Publisher Site
http://dx.doi.org/10.1200/JCO.2007.11.5964DOI Listing
September 2008

Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment.

Cancer Res 2008 Sep;68(17):6942-52

Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-0347DOI Listing
September 2008

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.

Clin Cancer Res 2008 Feb;14(4):957-60

Department of Medical Oncology, Azienda Unità Sanitaria Locale Bellaria-Maggiore Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1810DOI Listing
February 2008

Chemoradiotherapy in malignant glioma: standard of care and future directions.

J Clin Oncol 2007 Sep;25(26):4127-36

Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.11.8554DOI Listing
September 2007

MGMT methylation status: the advent of stratified therapy in glioblastoma?

Dis Markers 2007 ;23(1-2):97-104

Klinikum der Universität Regensburg, Klinik und Poliklinik für Neurologie am Bezirksklinikum, 93053 Regensburg, Germany.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851641PMC
http://dx.doi.org/10.1155/2007/159242DOI Listing
May 2007

Methylguanine methyltransferase testing in glioblastoma: when and how?

J Clin Oncol 2007 Apr;25(12):1459-60

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.09.7139DOI Listing
April 2007

Targeting brain-tumor stem cells.

Nat Biotechnol 2007 Feb;25(2):193-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt0207-193DOI Listing
February 2007

Neuro-oncology: oligodendroglioma and molecular markers.

Lancet Neurol 2007 Jan;6(1):10-2

Multidisciplinary Oncology Centre and Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University of Lausanne Hospitals, 1011 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(06)70663-9DOI Listing
January 2007

New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.

Neurosurg Focus 2006 Apr 15;20(4):E6. Epub 2006 Apr 15.

Department of Neurosurgery, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/foc.2006.20.4.3DOI Listing
April 2006

Recent developments in the use of chemotherapy in brain tumours.

Eur J Cancer 2006 Mar 20;42(5):582-8. Epub 2006 Jan 20.

Department of Neuro-Oncology, Daniel den Hoed Cancer Center/Erasmus University Hospital Rotterdam, P.O. Box 5201, 3008AE Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2005.06.031DOI Listing
March 2006

Changing paradigms--an update on the multidisciplinary management of malignant glioma.

Oncologist 2006 Feb;11(2):165-80

Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.11-2-165DOI Listing
February 2006

Correlative studies in neuro-oncology trials: should they influence treatment?

Curr Oncol Rep 2006 Jan;8(1):54-7

Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne (CHUV), 1011 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-006-0010-zDOI Listing
January 2006

Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice.

Toxicol Pathol 2005 ;33(3):307-12

Laboratory of Experimental Pathology National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01926230590922848DOI Listing
July 2005

Optimal role of temozolomide in the treatment of malignant gliomas.

Curr Neurol Neurosci Rep 2005 May;5(3):198-206

Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 rue du Bugnon, Lausanne 1011, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11910-005-0047-7DOI Listing
May 2005

Growth promoting signaling by tenascin-C [corrected].

Cancer Res 2004 Oct;64(20):7377-85

Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-1234DOI Listing
October 2004

INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma.

Oncogene 2004 Sep;23(41):6854-63

Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital (CHUV), BH19-110, Lausanne 1011, Switzerland.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1207872
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1207872DOI Listing
September 2004

Prognostic factors for low-grade gliomas.

Semin Oncol 2003 Dec;30(6 Suppl 19):23-8

Multidisciplinary Oncology Center, University Hospital (CHUV), 46, Rue du Bugnon, CH-1011 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2003.11.029DOI Listing
December 2003

Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.

Oncogene 2002 Jun;21(27):4212-9

Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hosptial Lausanne, 1011 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1205610DOI Listing
June 2002